Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4317-4327

  Blaney Jr , Joseph E ^a   Manipon, Gracielle G ^a   Firestone, Cai Yen ^a   Johnson, Daniel H ^a   Hanson, Christopher T ^a   Murphy, Brian R ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adaptation; Dengue; Vaccine; Vero cells

Indexed keywords

DENGUE VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADAPTATION; ANIMAL CELL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; BRAIN; CONTROLLED STUDY; DENGUE VIRUS; GENETIC CODE; KINETICS; MISSENSE MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VERO CELL; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TYPING;

EID: 0346186973     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00487-0     Document Type: Article

References (54)

1. Rice CM. Flaviviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology. Philadelphia: Lippincott-Raven Publishers; 1996;931-59.
2. Chang G-J. Molecular biology of dengue viruses. In: Gubler DJ, Kuno G, editors. Dengue and dengue hemorrhagic fever. New York: CAB International; 1997;175-98.
3. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11(3):1998;480-496.
4. Gubler D.J., Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 53:1999;35-70.
5. Innis BL. Dengue and dengue hemorrhagic fever. In: Porterfield JS, editor. Exotic viral infections. London: Chapman & Hall; 1995;103-46.
6. Almond J., Clemens J., Engers H.et al. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. Vaccine. 20(25-26):2002;3043-3046.
7. Rothman A.L., Ennis F.A. Immunopathogenesis of dengue hemorrhagic fever. Virology. 257(1):1999;1-6.
8. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science. 239(4839):1988;476-481.
9. Kanesa-thasan N., Sun W., Kim-Ahn G.et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 19:2001;3179-3188.
10. Edelman R., Tacket C.O., Wasserman S.S.et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J. Infect. Dis. 170(6):1994;1448-1455.
11. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. In: Gubler DJ, Kuno G, editors. Dengue and dengue hemorrhagic fever. New York: CAB International; 1997;367-77.
12. Whitehead S.S., Falgout B., Hanley K.A., Blaney J.E. Jr., Markoff L., Murphy B.R. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77(2):2003;1653-1657.
13. Huang C.Y., Butrapet S., Pierro D.J.et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74(7):2000;3020-3028.
14. Guirakhoo F., Pugachev K., Arroyo J.et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 298(1):2002;146-159.
15. Durbin A.P., Karron R.A., Sun W.et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hygiene. 65(5):2001;405-413.
16. Whitehead S, Hanley K, Blaney J, Gilmore L, Elkins W, Murphy B. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003;21(27-28):4307-16.
17. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. U.S.A. 99(5):2002;3036-3041.
18. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl. Acad. Sci. U.S.A. 89(21):1992;10532-10536.
19. Srivastava A.K., Putnak J.R., Lee S.H.et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine. 19(31):2001;4557-4565.
20. Montagnon B, Vincent-Falquet J. Experience with the Vero cell line. In: Brown F, Griffths E, Horaud F, Petricciani J, editors. Safety of biological products prepared from mammalian cell culture. Basel: Karger; 1998;119-23.
21. Dunster L.M., Wang H., Ryman K.D.et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology. 261(2):1999;309-318.
22. Theiler M., Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:1937;787-800.
23. Lee E., Weir R.C., Dalgarno L. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology. 232(2):1997;281-290.
24. Puri B., Nelson W.M., Henchal E.A.et al. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J. Gen. Virol. 78(9):1997;2287-2291.
25. Blaney J., Johnson D., Manipon G.et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 300(1):2002;125.
26. Blaney J.E. Jr., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J. Virol. 75(20):2001;9731-9740.
27. Itoh M., Isegawa Y., Hotta H., Homma M. Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells. J. Gen. Virol. 78(12):1997; 3207-3215.
28. Emerson S.U., Huang Y.K., Purcell R.H. 2B and 2C mutations are essential but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology. 194(2):1993;475-480.
29. Takeda M., Kato A., Kobune F.et al. Measles virus attenuation associated with transcriptional impediment and a few amino acid changes in the polymerase and accessory proteins. J. Virol. 72(11):1998;8690-8696.
30. Macadam A.J., Ferguson G., Burlison J.et al. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology. 189(2):1992;415-422.
31. Mandl C.W., Kroschewski H., Allison S.L.et al. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J. Virol. 75(12):2001;5627-5637.
32. Lobigs M., Usha R., Nestorowicz A., Marshall I.D., Weir R.C., Dalgarno L. Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence. Virology. 176(2):1990;587-595.
33. Cao J.X., Ni H., Wills M.R.et al. Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice. J. Gen. Virol. 76(11):1995;2757-2764.
34. Blok J., McWilliam S.M., Butler H.C.et al. Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses. Virology. 187(2):1992;573-590.
35. Vlaycheva L.A., Chambers T.J. Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J. Virol. 76(12):2002;6172-6184.
36. McMinn P.C., Marshall I.D., Dalgarno L. Neurovirulence and neuroinvasiveness of Murray Valley encephalitis virus mutants selected by passage in a monkey kidney cell line. J. Gen. Virol. 76(4):1995;865-872.
37. Butrapet S., Huang C.Y., Pierro D.J., Bhamarapravati N., Gubler D.J., Kinney R.M. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74(7):2000;3011-3019.
38. Hahn C.S., Dalrymple J.M., Strauss J.H., Rice C.M. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl. Acad. Sci. U.S.A. 84(7):1987;2019-2023.
39. Wu S.C., Lee S.C. Complete nucleotide sequence and cell-line multiplication pattern of the attenuated variant CH2195LA of Japanese encephalitis virus. Virus Res. 73(1):2001;91-102.
40. Wu S.C., Lian W.C., Hsu L.C., Liau M.Y. Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res. 51(2):1997;173-181.
41. Jennings A.D., Gibson C.A., Miller B.R.et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169(3):1994;512-518.
42. Ni H., Chang G.J., Xie H., Trent D.W., Barrett A.D. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol. 76(2):1995;409-413.
43. Chambers T.J., Hahn C.S., Galler R., Rice C.M. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:1990;649-688.
44. Westaway E.G., Khromykh A.A., Kenney M.T., Mackenzie J.M., Jones M.K. Proteins C and NS4B of the flavivirus Kunjin translocate independently into the nucleus. Virology. 234(1):1997;31-41.
45. Lin C., Wu J.W., Hsiao K., Su M.S. The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A proteins. J. Virol. 71(9):1997;6465-6471.
46. Lin C., Amberg S.M., Chambers T.J., Rice C.M. Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J. Virol. 67(4):1993;2327-2335.
47. Qu L., McMullan L.K., Rice C.M. Isolation and characterization of noncytopathic pestivirus mutants reveals a role for nonstructural protein NS4B in viral cytopathogenicity. J. Virol. 75(22):2001;10651-10662.
48. Rezapkin G.V., Fan L., Asher D.M., Fibi M.R., Dragunsky E.M., Chumakov K.M. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype. Virology. 258(1):1999;152-160.
49. Rezapkin G.V., Norwood L.P., Taffs R.E., Dragunsky E.M., Levenbook I.S., Chumakov K.M. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control. Virology. 211(2):1995;377-384.
50. Pletnev A.G., Bray M., Hanley K.A., Speicher J., Elkins R. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J. Virol. 75(17):2001;8259-8267.
51. Markoff L., Pang X., Houng H.S.et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76(7):2002;3318-3328.
52. Skiadopoulos M.H., Surman S.R., St Claire M., Elkins W.R., Collins P.L., Murphy B.R. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L-polymerase mutation. Virology. 260(1):1999;125-135.
53. Durbin A.P., McAuliffe J.M., Collins P.L., Murphy B.R. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology. 261(2):1999;319-330.
54. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine. 16(9-10):1998;960-968.